Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Core Content for Wilderness Medicine Training: Development of a Wilderness Medicine Track Within an Emergency Medicine Residency
Schrading, Walter A. , Battaglioli, Nicole , Drew, Jonathan , McClure, Sarah Frances

Mayo Clinic

Wilderness & Environmental Medicine | January 17, 2018 | Volume: 29 | Issue: 1 | Pages: 78-84

10.1016/j.wem.2017.10.003 | PMID 29373220 Get It

Wilderness medicine training has become increasingly popular among medical professionals with numerous educational opportunities nationwide. Curricula for fellowship programs and for medical student education have previously been developed and published, but a specific curriculum for wilderness medicine education during emergency medicine (EM) residency has not. The objective of this study is to create a longitudinal wilderness medicine curriculum that can be incorporated into an EM residency program. Interest-specific tracks are becoming increasingly common in EM training. We chose this model to develop our curriculum specific to wilderness medicine. Outlined in the article is a 3-year longitudinal course of study that includes a core didactic curriculum and a plan for graduated level of responsibility. The core content is specifically related to the required EM core content for residency training with additions specific to wilderness medicine for the residents who pursue the track. The wilderness medicine curriculum would give residencies a framework that can be used to foster learning for residents interested in wilderness medicine. It would enhance the coverage of wilderness and environmental core content education for all EM residents in the program. It would provide wilderness-specific education and experience for interested residents, allowing them to align their residency program requirements through a focused area of study and enhancing their curriculum vitae at graduation. Finally, given the popularity of wilderness medicine, the presence of a wilderness medicine track may improve recruitment for the residency program.
Improving Resiliency in Healthcare Employees
Werneburg, Brooke L., Jenkins, Sarah M. , Friend, Jamie L., Berkland, Bridget E., Clark, Matthew M. , Rosedahl, Jordan K., Preston, Heather R., Daniels, Denise C., Riley, Beth A., Olsen, Kerry D., Sood, Amit , Friend, Jamie L.

Mayo Clinic

American Journal of Health Behavior | January 10, 2018 | Volume: 42 | Issue: 1 | Pages: 39-50

10.5993/ajhb.42.1.4 | PMID 29320337 Get It

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
Tissino, Erika , Benedetti, Dania , Herman, Sarah E. M. , Hacken, Elisa ten , Ahn, Inhye E. , Chaffee, Kari G. , Rossi, Francesca Maria , Bo, Michele Dal , Bulian, Pietro , Bomben, Riccardo , Bayer, Elisabeth, Härzschel, Andrea, Gutjahr, Julia , Santinelli, Enrico , Ayed, Ayed O. , Zaja, Francesco , Chiarenza, Annalisa , Pozzato, Gabriele , Chigaev, Alexandre , Sklar, Larry A. , Hartmann, Tanja Nicole , Gattei, Valter , Zucchetto, Antonella , Rabe, Kari G. , Ayed, Ayed , Chiarenza, Annalisa , Zucchetto, Antonella , Postorino, Massimiliano , Burger, Jan A. , Ferrajoli, Alessandra , Shanafelt, Tait D. , Wiestner, Adrian U. , Poeta, Giovanni Del

Mayo Clinic

Journal of Experimental Medicine | January 4, 2018 | Volume: 215 | Issue: 2 | Pages: 681-697

10.1084/jem.20171288 | PMID 29301866 Get It

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating to retain the tumor cells in nodal compartments. Here, we show that the VLA-4 integrin, as expressed by CD49d-positive CLL, can be inside-out activated upon BCR triggering, thus reinforcing the adhesive capacities of CLL cells. In vitro and in vivo ibrutinib treatment, although reducing the constitutive VLA-4 activation and cell adhesion, can be overcome by exogenous BCR triggering in a BTK-independent manner involving PI3K. Clinically, in three independent ibrutinib-treated CLL cohorts, CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival, suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4. Evaluation of CD49d expression should be incorporated in the characterization of CLL undergoing therapy with BCR inhibitors.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HE
Cramer, Paula , Fraser, Graeme , Santucci-Silva, Rodrigo, Grosicki, Sebastian , Dilhuydy, Marie‐Sarah, Janssens, Ann , Loscertales, Javier , Rule, Simon , Traina, Shana, Chan, Eric K. H., Diels, Joris , Sengupta, Nishan , Mahler, Michelle, Salman, Mariya, Howes, Angela, Chanan‐Khan, Asher , Chanan-Khan, Asher, Dilhuydy, Marie‐Sarah, Goy, Andre Henri

Mayo Clinic

Leukemia & Lymphoma | January 3, 2018 | Volume: 59 | Issue: 9 | Pages: 2075-2084

10.1080/10428194.2017.1416364 | PMID 29295653 Get It

Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction
Huang, Yu-Li, Bryce, Alan H. , Culbertson, Tracy, Connor, Sarah L., Looker, Sherry, Altman, Kristin M., Collins, James , Stellner, Winston, Moreno‐Aspitia, Alvaro , Looker, Sherry A, Collins, James G, McWilliams, Robert R. , Bryce, Alan H , Culbertson, Tracy L, Ailawadhi, Sikander , Mesa, Ruben A.

Mayo Clinic

Journal of Oncology Practice | December 22, 2017 | Volume: 14 | Issue: 2 | Pages: e82-e91

10.1200/jop.2017.025510 | PMID 29272201 Get It

Introduction: Optimal scheduling and calendar management in an outpatient chemotherapy unit is a complex process that is driven by a need to focus on safety while accommodating a high degree of variability. Primary constraints are infusion times, staffing resources, chair availability, and unit hours. Methods: We undertook a process to analyze our existing management models across multiple practice settings in our health care system, then developed a model to optimize safety and efficiency. The model was tested in one of the community chemotherapy units. We assessed staffing violations as measured by nurse-to-patient ratios throughout the workday and at key points during treatment. Staffing violations were tracked before and after the implementation of the new model. Results: The new model reduced staffing violations by nearly 50% and required fewer chairs to treat the same number of patients for the selected clinic day. Actual implementation results indicated that the new model leveled the distribution of patients across the workday with an 18% reduction in maximum chair utilization and a 27% reduction in staffing violations. Subsequently, a positive impact on peak pharmacy workload reduced delays by as much as 35 minutes. Nursing staff satisfaction with the new model was positive. Conclusion: We conclude that the proposed optimization approach with regard to nursing resource assignment and workload balance throughout a day effectively improves patient service quality and staff satisfaction.
Genome U-Plot: a whole genome visualization
Gaitatzes, Athanasios , Johnson, Sarah H. , Smadbeck, James B. , Vasmatzis, George

Mayo Clinic

Bioinformatics | December 20, 2017 | Volume: 34 | Issue: 10 | Pages: 1629-1634

10.1093/bioinformatics/btx829 | PMID 29281001 Get It

Abstract Motivation The ability to produce and analyze whole genome sequencing (WGS) data from samples with structural variations (SV) generated the need to visualize such abnormalities in simplified plots. Conventional two-dimensional representations of WGS data frequently use either circular or linear layouts. There are several diverse advantages regarding both these representations, but their major disadvantage is that they do not use the two-dimensional space very efficiently. We propose a layout, termed the Genome U-Plot, which spreads the chromosomes on a two-dimensional surface and essentially quadruples the spatial resolution. We present the Genome U-Plot for producing clear and intuitive graphs that allows researchers to generate novel insights and hypotheses by visualizing SVs such as deletions, amplifications, and chromoanagenesis events. The main features of the Genome U-Plot are its layered layout, its high spatial resolution and its improved aesthetic qualities. We compare conventional visualization schemas with the Genome U-Plot using visualization metrics such as number of line crossings and crossing angle resolution measures. Based on our metrics, we improve the readability of the resulting graph by at least 2-fold, making apparent important features and making it easy to identify important genomic changes. Results A whole genome visualization tool with high spatial resolution and improved aesthetic qualities. Availability and implementation An implementation and documentation of the Genome U-Plot is publicly available at https://github.com/gaitat/GenomeUPlot. Supplementary information Supplementary data are available at Bioinformatics online.
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
Molenaar, Remco J. , Sidana, Surbhi , Gerds, Aaron T. , Angelini, Dana E. , Kalaycio, Matt, Nazha, Aziz , Adelstein, David J. , Nasr, Christian , Maciejewski, Jaroslaw P. , Majhail, Navneet S. , Sekeres, Mikkael A. , Radivoyevitch, Tomas, Advani, Anjali S. , Angelini, Dana, Mukherjee, Sudipto, Gerds, Aaron T , Majhail, Navneet S , Sidana, Surbhi , Sekeres, Mikkael A , Radivoyevitch, Tomas , Carraway, Hetty E. , Mukherjee, Sudipto

Mayo Clinic

Journal of Clinical Oncology | December 18, 2017 | Volume: 36 | Issue: 18 | Pages: 1831-1839

10.1200/jco.2017.75.0232 | PMID 29252123 Get It

Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive iodine (RAI). Methods Patients with WDTC were identified from SEER registries. Competing risk regression analysis was performed to calculate the risks of SHMs that occurred after WDTC treatment and outcomes after SHM development were assessed. Results Of 148,215 patients with WDTC, 53% received surgery alone and 47% received RAI. In total, 783 patients developed an SHM after a median interval of 6.5 years (interquartile range, 3.3 to 11.2 years) from WDTC diagnosis. In multivariable analysis, compared with those undergoing thyroidectomy alone, RAI treatment was associated with an increased early risk of developing acute myeloid leukemia (AML; hazard ratio, 1.79; 95% CI, 1.13 to 2.82; P = .01) and chronic myeloid leukemia (CML; hazard ratio, 3.44; 95% CI, 1.87 to 6.36; P < .001). This increased risk of AML and CML after RAI treatment was seen even in low-risk and intermediate-risk WDTC tumors. Occurrence of AML but not CML in patients with WDTC was associated with shorter median overall survival compared with matched controls (8.0 years v 31.0 years; P = .001). In addition, AML developing after RAI trended toward inferior survival compared with matched controls with de novo AML (median overall survival, 1.2 years v 2.9 years; P = .06). Conclusion Patients with WDTC treated with RAI had an increased early risk of developing AML and CML but no other hematologic malignancies. AML that arises after RAI treatment has a poor prognosis. RAI use in patients with WDTC should be limited to patients with high-risk disease features, and patients with WDTC treated with adjuvant RAI should be monitored for myeloid malignancies as part of cancer surveillance.
Surveillance for and Discovery of Borrelia Species in US Patients Suspected of Tickborne Illness
Kingry, Luke C. , Anacker, Melissa , Pritt, Bobbi S. , Bjork, Jenna , Respicio-Kingry, Laurel, Liu, Gong‐Ping , Sheldon, Sarah W., Boxrud, David, Strain, Anna K., Oatman, Stephanie, Berry, Jon, Sloan, Lynne M., Mead, Paul S. , Neitzel, David F., Kugeler, Kiersten J. , Petersen, Jeannine M., Pritt, Bobbi, Sloan, Lynne, Kingry, Luke , Pritt, Bobbi S , Berry, Jonathan

Mayo Clinic

Clinical Infectious Diseases | December 17, 2017 | Volume: 66 | Issue: 12 | Pages: 1864-1871

10.1093/cid/cix1107 | PMID 29272385 Get It

Surfacing and addressing hospitalized patients’ needs: Proactive nurse rounding as a tool
Danaf, Jad Al, Chang, Bickey H. , Shaear, Mohammad , Johnson, Kristine M., Miller, Sandra, Nester, Lynda, Williams, Amy W. , Aboumatar, Hanan

Mayo Clinic

Journal of Nursing Management | December 16, 2017 | Volume: 26 | Issue: 5 | Pages: 540-547

10.1111/jonm.12580 | PMID 29243363 Get It

Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction
Fayyaz, Ahmed, Edwards, William D. , Maleszewski, Joseph J. , Konik, Ewa, Borlaug, Barry A. , Frantz, Robert P. , Jenkins, Sarah M. , Redfield, Margaret M. , Borlaug, Barry A , Frantz, Robert P , DuBrock, Hilary M.

Mayo Clinic

Circulation | December 15, 2017 | Volume: 137 | Issue: 17 | Pages: 1796-1810

10.1161/circulationaha.117.031608 | PMID 29246894 Get It

Background: We hypothesized that pulmonary venous hypertension in heart failure (HF) leads to predominate remodeling of pulmonary veins and that the severity of venous remodeling is associated with the severity of pulmonary hypertension (PH) in HF. Methods: Patients with HF (n=108; 53 preserved and 55 reduced ejection fraction) with PH (HF-PH; pulmonary artery systolic pressure [PASP] ≥40 mm Hg) were compared to normal controls (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17). In lung specimens from autopsy (control, HF-PH, and 7 PVOD) or surgery (10 PVOD), quantitative histomorphometry was performed in all analyzable arteries (n=4949), veins (n=7630), and small indeterminate vessels (IV; n=2168) to define percent medial thickness (arteries) and percent intimal thickness (%IT) (arteries, veins, and IV) relative to external diameter. Results: The average arterial percent medial thickness (control, 6.9; HF-PH, 11.0; PVOD, 15.0), arterial %IT (control, 4.9; HF-PH, 14.9; PVOD, 31.1), venous %IT (control, 14.0; HF-PH, 24.9; PVOD, 43.9), and IV %IT (control, 10.6; HF-PH, 25.8; PVOD, 50.0) in HF-PH were higher than controls ( P <0.0001 for all) but lower than PVOD ( P ≤0.005 for all). PASP (mm Hg) was lower in HF-PH (median, 59 [interquartile range, 50–70]) than in PVOD (median, 91 [interquartile range, 82–103]). PASP correlated with arterial percent medial thickness ( r =0.41) and arterial %IT ( r =0.35) but more strongly with venous %IT ( r =0.49) and IV %IT ( r =0.55) ( P <0.0001 for all). Associations between PASP and venous or IV %IT remained significant after adjusting for arterial percent medial thickness and %IT and did not vary by HF type. In patients with right heart catheterization (30 HF-PH, 14 PVOD), similar associations between the transpulmonary gradient and pulmonary vascular remodeling existed, with numerically stronger associations for venous and IV %IT. Although the PASP was slightly higher in patients with HF-PH with right ventricular dysfunction, pulmonary vascular remodeling was not more severe. Pulmonary vascular remodeling severity was associated with reductions in the diffusing capacity of the lungs. Conclusions: In HF, PH is associated with global pulmonary vascular remodeling, but the severity of PH correlates most strongly with venous and small IV intimal thickening, similar to the pattern observed in PVOD. These findings expand our understanding of the pathobiology of PH in HF.